We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Indications and Limitations of Vismodegib for Basal Cell Carcinoma—Reply

Harmeet S. Gill, MD, FRCSC1; Eve E. Moscato, MD2; Rona Z. Silkiss, MD3
[+] Author Affiliations
1Department of Ophthalmology and Vision Sciences, University of Toronto, Mount Sinai Hospital, Toronto, Ontario, Canada
2Division of Oculofacial Plastic and Orbital Surgery, California Pacific Medical Center, Oakland
3Division of Ophthalmic Plastic, Reconstructive, and Orbital Surgery, California Pacific Medical Center, Oakland
JAMA Ophthalmol. 2014;132(7):906. doi:10.1001/jamaophthalmol.2014.1805.
Text Size: A A A
Published online


In Reply Yin and colleagues make an excellent point highlighting the fact that the underlying mutation in patched homologue 1 is not altered by vismodegib. Of course, we agree that patients must continue to be monitored long-term after the drug is discontinued for possible recurrence and more prospective data with greater patient numbers are needed to better define the ideal duration of treatment.

Our study demonstrated complete clinical regression in 2 of the 7 patients with a relatively short duration of therapy. Although Tang et al1 found that 6 of 13 biopsy specimens showed residual tumor after 3 months of therapy, this study was looking exclusively at patients with basal cell nevus syndrome. Certainly it is reasonable to expect patients with basal cell nevus syndrome to be most likely to have tumor regrowth after discontinuation of the drug. Extrapolating these results to cases of nonsyndromic BCC may not be valid.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.